公开(公告)号：WO0196398A3

公开(公告)日：2002-05-16

申请号：PCT/US0119230

申请日：2001-06-15

Applicant: COR THERAPEUTICS INC ,  HOMCY CHARLES J

Inventor： HOMCY CHARLES J

IPC: C07K14/705 ,  A01K67/027 ,  A61K35/00 ,  C12Q1/00

CPC classification number: C07K14/705 ,  A01K2217/05

Abstract: The present invention provides methods of identifying an agent effective for the treatment of heart failure by modulating the expression or activity of uncoupling proteins (UCP). The present invention also provides compositions and methods for treating heart failure.

Abstract translation: 本发明提供了通过调节解偶联蛋白（UCP）的表达或活性来鉴定有效治疗心力衰竭的药剂的方法。 本发明还提供了治疗心力衰竭的组合物和方法。

公开(公告)号：WO2002017711A3

公开(公告)日：2002-03-07

申请号：PCT/US2001/026936

申请日：2001-08-31

Applicant: COR THERAPEUTICS, INC. ,  RAMAKRISHNAN, Vanitha ,  PHILLIPS, David

Inventor： RAMAKRISHNAN, Vanitha ,  PHILLIPS, David

IPC: A01K67/027

Abstract: The present invention relates to therapeutics and diagnostics that take advantage of a novel signal transduction pathway in platelets. In addition, the present invention provides methods for identifying agents that modulate activities mediated by the novel transduction pathway including platelet activation and thrombosis.

公开(公告)号：WO2001094331A3

公开(公告)日：2001-12-13

申请号：PCT/US2001/018014

申请日：2001-06-01

Applicant: ELI LILLY & COMPANY ,  COR THERAPEUTICS, INC. ,  ANTOINE, Luc ,  BOQUEL, Pascal ,  BORGHESE, Alfia ,  GORISSEN, Hugo ,  MARTINELLI, Michael ,  MERSCHAERT, Alain ,  RUHTER, Gerd ,  RYPENS, Carine ,  SCARBOROUGH, Robert ,  SCHOTTEN, Theo ,  VAN HOECK, Jean-Pierre

Inventor： ANTOINE, Luc ,  BOQUEL, Pascal ,  BORGHESE, Alfia ,  GORISSEN, Hugo ,  MARTINELLI, Michael ,  MERSCHAERT, Alain ,  RUHTER, Gerd ,  RYPENS, Carine ,  SCARBOROUGH, Robert ,  SCHOTTEN, Theo ,  VAN HOECK, Jean-Pierre

IPC: C07D311/70

Abstract: Disclosed are processes for producing benzopyran compounds, reduced 2-(chroman-2-yl) acetic acid compounds and 2-(6-aminochroman-2-yl)acetic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors.

公开(公告)号：WO0194331A2

公开(公告)日：2001-12-13

申请号：PCT/US0118014

申请日：2001-06-01

Applicant: LILLY CO ELI ,  COR THERAPEUTICS INC ,  ANTOINE LUC ,  BOUQUEL PASCAL ,  BORGHESE ALFIA ,  GORISSEN HUGO ,  MARTINELLI MICHAEL ,  MERSCHAERT ALAIN ,  RUHTER GERD ,  RYPENS CARINE ,  SCARBOROUGH ROBERT ,  SCHOTTEN THEO ,  HOECK JEAN PIERRE VAN

Inventor： ANTOINE LUC ,  BOUQUEL PASCAL ,  BORGHESE ALFIA ,  GORISSEN HUGO ,  MARTINELLI MICHAEL ,  MERSCHAERT ALAIN ,  RUHTER GERD ,  RYPENS CARINE ,  SCARBOROUGH ROBERT ,  SCHOTTEN THEO ,  VAN HOECK JEAN-PIERRE

IPC: C07D311/58 ,  C07D311/00

CPC classification number: C07D311/58

Abstract: Disclosed are processes for producing benzopyran compounds, reduced 2-(chroman-2-yl) acetic acid compounds and 2-(6-aminochroman-2-yl)acetic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors.

Abstract translation: 公开了制备苯并吡喃化合物，还原的2-（色满-2-基）乙酸化合物和2-（6-氨基苯并二氢吡喃-2-基）乙酸酯的方法，其为制备血小板聚集抑制剂的中间体和/或本身是有效的 血小板聚集抑制剂。

公开(公告)号：WO0119798A2

公开(公告)日：2001-03-22

申请号：PCT/US0025195

申请日：2000-09-15

Applicant: COR THERAPEUTICS INC

Inventor： ZHU BING-YAN ,  JIA ZHAOZHONG JON ,  HUANG WENRONG ,  SONG YONGHONG ,  KANTER JAMES ,  SCARBOROUGH ROBERT M

IPC: C07D231/14 ,  A61K31/33 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61P7/02 ,  A61P7/04 ,  A61P43/00 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C317/44 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D217/22 ,  C07D277/20 ,  C07D277/56 ,  C07D333/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D521/00 ,  C07D231/00

CPC classification number: C07D213/75 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C317/44 ,  C07D213/81 ,  C07D213/82 ,  C07D217/22 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D277/56 ,  C07D333/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds of formula A Q D E G J X in which D is a direct link, a substituted or unsubsituted phenyl or naphtyl gourp or a heterocyclic ring system; G is substituted or unsubstituted phenyl or a heterocyclic ring system; X is a substituted or unsubstituted phenyl or naphtyl group or a heterocyclic ring system; and the other variables are as defined in the claims, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed, The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract translation: 其中D是直接键，取代或未取代的苯基或萘基金属或杂环系的式A Q D E G J X的化合物; G是取代或未取代的苯基或杂环系; X是取代或未取代的苯基或萘基或杂环系; 并且其它变量如权利要求中所定义，其公开的与其相关的盐和组合物具有抗哺乳动物因子Xa的活性。该化合物在体外或体内可用于预防或治疗凝血障碍。

公开(公告)号：WO0071515A3

公开(公告)日：2001-01-25

申请号：PCT/US0014193

申请日：2000-05-24

Applicant: COR THERAPEUTICS INC

Inventor： ZHU BING-YAN ,  SCARBOROUGH ROBERT M

IPC: A61K31/155 ,  A61K31/18 ,  A61K31/275 ,  A61K31/401 ,  A61K31/402 ,  A61K31/451 ,  A61P7/02 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  C07C311/46 ,  C07D207/16 ,  C07D211/60 ,  C07D241/04 ,  C07D243/08 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  A61K31/40 ,  A61P7/00 ,  C07C311/39

CPC classification number: C07D401/04 ,  C07C311/46 ,  C07D207/16 ,  C07D211/60 ,  C07D241/04 ,  C07D243/08 ,  C07D403/04 ,  C07D413/04

Abstract: Compounds, e.g. described in Table (1), their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract translation: 化合物，例如 在表（1）中描述了它们与其相关的盐和组合物具有抗哺乳动物因子Xa的活性。 该化合物可用于体内或体内用于预防或治疗凝血障碍。

公开(公告)号：WO1998025892A1

公开(公告)日：1998-06-18

申请号：PCT/US1997022495

申请日：1997-12-08

Applicant: ELI LILLY AND COMPANY ,  COR THERAPEUTICS, INC. ,  FISHER, Matthew, J. ,  FRANCISKOVICH, Jeffry, Bernard ,  JAKUBOWSKI, Joseph, A. ,  MASTERS, John, J. ,  SCARBOROUGH, Robert, M. ,  SMYTH, Mark ,  SU, Ting

Inventor： ELI LILLY AND COMPANY ,  COR THERAPEUTICS, INC.

IPC: C07C311/00

CPC classification number: C07C311/06 ,  C07C311/19 ,  C07C2601/14 ,  C07D211/62

Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.

Abstract translation: 公开了与哺乳动物整联蛋白有关的新型化合物，其盐和与其有关的组合物。 该化合物在体外或体内可用于预防或治疗血栓形成或再狭窄病症。

公开(公告)号：WO1998016524A1

公开(公告)日：1998-04-23

申请号：PCT/US1997018410

申请日：1997-10-10

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  ZHU, Bing-Yan ,  SCARBOROUGH, Robert, M.

IPC: C07D417/14

CPC classification number: C07D413/14 ,  A61K38/00 ,  C07D417/12 ,  C07D417/14 ,  C07F5/025 ,  C07K5/06026 ,  C07K5/0821

Abstract: Novel compound, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract translation: 公开了具有抗哺乳动物因子Xa活性的新型化合物，其盐和与其有关的组合物。 该化合物在体外或体内可用于预防或治疗凝血障碍。

公开(公告)号：WO9720045A3

公开(公告)日：1997-06-26

申请号：PCT/US9618175

申请日：1996-11-08

Applicant: COR THERAPEUTICS INC

Inventor： CONLEY PAMELA B ,  JANTZEN HANS-MICHAEL

IPC: C12N15/09 ,  A61K38/00 ,  A61K48/00 ,  C07K14/705 ,  C12N15/12 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/566

CPC classification number: G01N33/5091 ,  A61K38/00 ,  A61K48/00 ,  C07K14/705 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/5041 ,  G01N33/5044 ,  G01N33/5094 ,  G01N33/566 ,  G01N2500/10

Abstract: Novel purinergic receptors are provided, having research, diagnostic and therapeutic applications. Also provided are nucleic acids encoding these receptors, as well as expression systems for their production.

公开(公告)号：WO1996023225A1

公开(公告)日：1996-08-01

申请号：PCT/US1996001179

申请日：1996-01-25

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  SUNDELIN, Johan ,  SCARBOROUGH, Robert, M.

IPC: G01N33/53

CPC classification number: C07K14/723 ,  A61K38/00 ,  A61K48/00

Abstract: Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.

Abstract translation: 编码C140细胞表面受体的核酸分子已被克隆并测序。 C140受体DNA的可用性允许重组产生可在细胞表面（包括卵母细胞）上产生的C140受体。 核酸分子可用于检测影响C140受体活性的物质，即受体激动剂或拮抗剂。 此外，阐明C140受体的结构允许设计可用于此类测定中的激动剂和拮抗剂化合物。 C140受体的可用性还允许产生与C140受体的一个或多个抗原表位特异性免疫反应的抗体。